– IRELAND, Dublin – Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the appointment of Dr. Billy Dunn (M.D.) to its Board of Directors.
AboutDr. Billy Dunn
Dr. Billy Dunn is the founding and former Director of the Office of Neuroscience, Center for Drug Evaluation and Research, at the U.S. Food and Drug Administration.
During his tenure at FDA, Dr. Dunn had a significant impact on how drugs are developed for a range of severe neurological diseases, including many that previously had only limited treatment options. His work and leadership contributed to major therapeutic advances in neuro-immunological diseases such as multiple sclerosis and myasthenia gravis, advances in rare neurological disorders, advances in migraine treatment, advances in the range of complex seizure disorders, and advances in therapies for Alzheimer’s disease, among many other neurological disorders.
Dr. Dunn is the founding director of the Office of Neuroscience, CDER, at the FDA, a position he held since the founding of the office in 2019 through February 2023. He was responsible for the regulatory oversight of all research conducted to support neuroscience drug development, including the regulation and review of investigational new drug applications and marketing applications for drug and biologic products. From 2005 to 2019, he held positions of increasing seniority in the Division of Neurology Products, CDER, including his role as director of that division.
Dr. Dunn is a trained neurologist and vascular neurologist with experience in basic research, clinical research, and clinical care. He earned his B.A. from the University of Virginia and his M.D. from the F. Edward Hébert School of Medicine in Bethesda, Maryland.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics that can potentially change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for several indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease, and several other neurodegenerative diseases.
Source: https://www.prothena.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.